AI Article Synopsis
- Membranous nephropathy (MN) is a rare complication that can occur after allogeneic hematopoietic stem cell transplantation (HSCT), and there isn't much long-term outcome data available.
- An adult female patient with follicular non-Hodgkin's lymphoma developed MN after her HSCT and was initially treated with methylprednisolone.
- After a relapse, she switched to rituximab, which led to a significant decrease in proteinuria and normalized her serum albumin, and she remains in remission seven months later without any adverse reactions to the treatment.
Article Abstract
Membranous nephropathy (MN) post allogeneic hematopoietic stem cell transplantation (HSCT) is a rare complication with few long-term outcome data. We describe the clinical course and outcome of an adult female patient who developed MN after allogeneic HSCT for follicular non-Hodgkin's lymphoma. MN was treated with methylprednisolone as first-line therapy, then she was changed to rituximab for a relapse. After treatment with rituximab, we observed a progressive decrease of proteinuria and normalization of serum albumin. Seven months after treatment, she remains in remission. No adverse reactions to rituximab were observed throughout follow-up.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!